Most clinical anti-EGFR antibodies do not neutralize both wtEGFR and EGFRvIII activation in glioma

BACKGROUND: Although epidermal growth factor receptor (EGFR) and its truncated, autoactive mutant EGFR variant (v)III are bona fide drivers of tumorigenesis in some gliomas, therapeutic antibodies developed to neutralize this axis have not improved patient survival in a limited number of trials. Pre...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neuro Oncol
Asıl Yazarlar: Greenall, Sameer A, McKenzie, Mathew, Seminova, Ekatarina, Dolezal, Olan, Pearce, Lesley, Bentley, John, Kuchibhotla, Mani, Chen, Shengnan C, McDonald, Kerrie L, Kornblum, Harley I, Endersby, Raelene, Adams, Timothy E, Johns, Terrance G
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2019
Konular:
Basic and Translational Investigations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6682217/
https://ncbi.nlm.nih.gov/pubmed/31002307
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz073
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller